Automated urinalysis systems
Roche's product portfolio includes three systems for urinary diagnostics, all of which use the proven Combur test strips.
Prostate cancer
New ways of working: innovation in cancer nursing practice
Change is occurring at a rapid rate in cancer care - in many European countries cancer services are now being provided primarily in an ambulatory or outpatient setting with subsequent change of resources. Karen Luker, Professor of Community Nursing at the Universtiy of Manchester, UK, thinks that specialist nurses should not only refresh their knowledge of existing and new therapies. As the face…
The European Study of Screening for Prostate Cancer (ERSPC)
The ERSPC is the world's biggest study of screening of prostate cancer. It involves up to 260,000 men, 220,000 of them in the age group 55-75 years old. Professor Chris Bangma, Director of the ERSPC and Chairman of the urology department at the Erasmus Medical Centre, Rotterdam (headquarters of the ERSPC) explains the study's background and aims
FRANCE: Thousands will lose healthcare cover
"If you think 53 makes you old enough to retire, then fine, go ahead and retire. But don't expect the state to pay for it." President Nicolas Sarkozy, during his election campaign
Embracing Excellence in Prostate and Kidney Cancer
The first European Multidisciplinary Meeting on Urological Cancers will take place in Barcelona, Spain, November 2nd to 4th, 2007. The meeting is co-organized by the European Association of Urology (EAU), the European Society for Medical Oncology (ESMO) and the European Society for Therapeutic Radiology and Oncology (ESTRO).
Taking a dive into the 21st Computer Assisted Radiology and Surgery Congress
Emphasis on advances in the use of computer assisted radiology and surgery (CARS) technologies in clinical diagnoses and therapies, will herald the opening of CARS this year.
In-vivo and in-vitro diagnostics in molecular medicine
In molecular medicine - and particularly in oncology - Siemens Medical Solutions is concentrating on further development of the FDG (fluorodeoxyglucose) biomarker to improve identification of certain tumours.
Transrectal Ultrasound in Prostate Cancer: State of the Art
The current prostate cancer disease burden is considerable due to the high prevalence of the disease, widespread early detection, and the relatively long survival time since many men will die with rather than due to prostate cancer. In the United States, one in every three new cases of cancer in men is prostate cancer. Worldwide, in 2002, it was predicted that 679,023 men received the diagnosis…
Prostate cancer
The Martini Clinic, a private clinic located at the Hamburg-Eppendorf University Hospital (UKE), specialises exclusively in the diagnosis and therapy of one medical condition: prostate cancer.
Variations in urological residencies
Urology is a surgical speciality with a limited number of consultants in Europe (around 134,000). The field is very well organised and active.
New Cancer Drug Hope
AstraZeneca has been collaborating with researchers who detected a potential Aurora B inhibitor.
Small wireless device to improve cancer treatment
USA - Engineers are developing a tiny wireless device - the size of a rice grain - to be implanted in tumours to indicate the precise radiation dose received and to locate the exact position of tumours during treatment.
Multifunctional lithotripter
Lithoskop, a new multifunctional lithotripsy system, is to be publicly launched by Siemens Medical Solutions at the European Association of Urology Congress, to be held in Istanbul, Turkey this March.
Alcohol ups colon cancer risk
Denmark - Regular drinkers significantly increase their risk of rectal cancer, but that risk is reduced if wine makes up a third or more of weekly consumption, according to research carried out by Professor Morten Grønbaek, at the Centre for Alcohol Research, National Institute of Public Health, Copenhagen, published in the journal GUT.
Hormone-resistant prostate cancer
Prostate cancer, the most common neoplasm in men, often progresses from an androgen-dependant state (and is commonly treated by androgen ablation therapies) to a hormone-refractory stage, therefore making hormone therapy ineffective. The response duration to androgen ablation therapy is finite and ultimately most prostate cancer will become hormone-insensitive.
A new cutting mode for TUR-P
Dry Cut, a new cutting mode produced specifically for transurethral resection of the prostate (TUR-P), has been launched by Erbe Elektromedizin, of Tubingen, Germany. This, with High Cut and Auto Cut, means that Erbes VIO System now offers the entire range of cutting qualities needed for TUR-P, TUR-B and TUV-P procedures, the firm reports.
MI treatment forbenign prostatic hyperplasia
An interview with Dr Andre Roggan, head of research and development at Celon AG, and Dr Markus Mueller, consultant at the Urology Clinic at the University Clinic Benjamin Franklin, Free University Berlin. Venue: 1st International Workshop on Radio-frequency Induced Thermotherapy (RFITT) for the treatment of BPH
Article • Research, diagnostics, therapy
Focus on prostate cancer
Prostate cancer (PCa) is not only one of the most common, but also one of the deadliest types of cancer in men. Diagnostics are correspondingly sophisticated, from imaging via ultrasound or MRI to various biopsy techniques – often even in combination. Keep reading for current developments in early detection, staging, therapy and research.
